Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 15/20 | 1.00 |
| ▸ | ABL1 | P00519 | 9/20 | 1.00 |
| ▸ | EGFR | P00533 | 3/20 | 1.00 |
| ▸ | KDR | P35968 | 3/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | YES1 | P07947 | 2/20 | 1.00 |
| ▸ | LYN | P07948 | 2/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 2/20 | 1.00 |
| ▸ | PRKACA | P17612 | 2/20 | 1.00 |
| ▸ | FRK | P42685 | 2/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 2/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 2/20 | 1.00 |
| ▸ | BLK | P51451 | 2/20 | 1.00 |
| ▸ | BTK | Q06187 | 2/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 2/20 | 1.00 |
| ▸ | SRMS | Q9H3Y6 | 2/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL375322 | 1.00 | SRC (1.00) | SRCABL1EGFRKDRRIPK2 | |
| Hydrochloric Acid SCHEMBL3784318 | 0.99 | SRC (0.97) | SRCABL1EGFRKDRRIPK2 | |
| SCHEMBL14617301 | 0.93 | SRC (0.89) | SRCABL1EGFRKDRRIPK2 | |
| SCHEMBL409444 | 0.89 | SRC (0.82) | SRCABL1EGFRKDRRIPK2 | |
| SCHEMBL29432587 | 0.88 | SRC (1.00) | SRCABL1EGFRKDRRIPK2 | |
| SCHEMBL407934 | 0.88 | SRC (1.00) | SRCABL1EGFRKDRRIPK2 | |
| SCHEMBL15114667 | 0.87 | SRC (0.77) | SRCABL1EGFRKDRRIPK2 | |
| SCHEMBL10098380 | 0.87 | SRC (0.77) | SRCABL1EGFRKDRRIPK2 | |
| SCHEMBL13019680 | 0.87 | SRC (0.77) | SRCABL1EGFRKDRRIPK2 | |
| SCHEMBL3610160 | 0.86 | SRC (0.95) | SRCABL1EGFRKDRRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4358982-A2 | PRIMORDIAL GERM CELLS | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2024-05-01 | — | — | EP | claimed |
| WO-2022272042-A2 | PRIMORDIAL GERM CELLS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2022-12-29 | — | — | WO | claimed |
| EP-4077690-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | Engine Biosciences Pte. Ltd. (SG) | 2022-10-26 | — | — | EP | claimed |
| CN-122059926-A | Heterocyclic degradation determinants for target protein degradation | C4医药公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4735452-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4665720-A2 | ISOINDOLINONE GLUTARIMIDE AND PHENYL GLUTARIMIDE ANALOGS AS DEGRADERS OF RET KINASE | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4611901-A1 | RET-LDD PROTEIN DEGRADERS | Bristol-Myers Squibb Company (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4611900-A1 | RET-LDD PROTEIN INHIBITORS | Bristol-Myers Squibb Company (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-2025129116-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| EP-4565585-A1 | COMPOUNDS FOR MODULATING RET PROTEIN | Bristol-Myers Squibb Company (US) | 2025-06-11 | — | — | EP | disclosed |
| WO-2025096856-A1 | COVALENT CEREBLON LIGANDS | C4 THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-115443132-A | Controlled delivery of chromancarlin prodrugs | 奎拉里斯生物公司 | 2022-12-06 | — | — | CN | disclosed |
| WO-2022251539-A2 | EGFR DEGRADERS TO TREAT CANCER METASTASIS TO THE BRAIN OR CNS | C4 THERAPEUTICS, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| CN-108367079-B | Aggregated microparticles for therapy | 灰色视觉公司 | 2022-11-22 | — | — | CN | disclosed |
| CN-115279370-A | Compounds for targeted degradation of BRD9 | C4医药公司 | 2022-11-01 | — | — | CN | disclosed |
| EP-4076450-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-114901277-A | Isoindolinone and indazole compounds for EGFR degradation | C4医药公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-114469872-A | Aggregate microparticles for therapy | 灰色视觉公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-108699024-B | Benzothienyl selective estrogen receptor down-regulator compounds | 伊利诺伊大学评议会 | 2022-03-11 | — | — | CN | disclosed |
| EP-3941462-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |